Sobol EK, Sakai Y, Wheelwright D, et al. - In this retrospective consecutive interventional case series, researchers sought to examine the benefit of early intra-arterial tissue plasminogen activator (IAT) for treatment of central retinal artery occlusion (CRAO). Fifteen patients (15 eyes) presenting with acute CRAO were included in this investigation. Patients were rejected if treatment with IAT was not started within 12 hours. An ophthalmologist confirmed the diagnosis. In this small uncontrolled study, IAT was safe and showed significant visual improvement. Larger studies and efforts to reduce treatment time should be initiated in order to optimize outcomes. No major adverse events have been recorded.